
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. is experiencing positive trends in the placement and utilization of its Revio sequencing platform, which is crucial for both near-term guidance and long-term targets through 2026. The company has expressed confidence in returning to growth this year, which is supported by its strong organic profile and recent strategic acquisitions that suggest potential for further market expansion. Although management may adopt a conservative approach to initial 2024 guidance due to the uncertain macro environment, the overall trajectory indicates a robust outlook for the company's financial performance.
Bears say
Pacific Biosciences faces significant risks related to stagnant utilization rates and potentially weaker demand for its instruments, which pose a threat to meeting its 2026 financial targets. Additionally, ongoing demand weaknesses, particularly in China, may persist into 2024, further damaging the company's revenue prospects if competitors introduce superior offerings. Compounding these challenges, the tightening of research budgets and reduced funding availability could limit customer purchases, negatively impacting Pacific Biosciences's growth potential.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares